Ask about this productRelated genes to: ZNF582 Blocking Peptide
- Gene:
- ZNF582 NIH gene
- Name:
- zinc finger protein 582
- Previous symbol:
- -
- Synonyms:
- FLJ30927
- Chromosome:
- 19q13.43
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-15
- Date modifiied:
- 2015-01-12
Related products to: ZNF582 Blocking Peptide
Related articles to: ZNF582 Blocking Peptide
- The methylation of PAX1 and ZNF582 has been proven to have good diagnostic efficacy to detect cervical precancerous lesions in Asian populations, but their performance in Dutch populations is still unclear. We assessed PAX1 and ZNF582 methylation in both Dutch and Chinese cohorts. - Source: PubMed
Publication date: 2026/05/22
Li NaHu Yuanjingvan der Zee Ate G JSchuuring EdWisman G Bea A - Human papillomavirus (HPV) gene transcription activity and methylation could be promising tools for cervical cancer (CC) screening. This study compared HPV E6/E7 messenger RNA (mRNA) + ThinPrep cytology test (TCT) vs. HPV genotyping + TCT in screening CC and explored the relationship between gene methylation and cervical lesions. - Source: PubMed
Publication date: 2026/04/22
Zhao XinlingChang LeiDuan WenyanLiu LijuanShi YangeFan XiaolingBai YuWang YanliLi Jingya - With the rapid development and maturation of high-risk human papillomavirus (hrHPV) genotyping kits, it is crucial to understand the specific patterns of methylation in different hrHPV statuses, rather than simply categorizing them as hrHPV positive or negative. To achieve this goal, we first assessed the prevalence and CIN3+ risk of specific hrHPV genotypes in 184 cervical scrapings and then evaluated the performance of five host genes methylation to distinguish CIN3+ from Jiang HaoZhu PengChen YanXiong JingChen PuxiangLi Qing
- Clear cell renal cell carcinoma (ccRCC) remains poorly understood at the genetic level. In this study, 12 GEO microarray datasets were combined, and meta-analysis and multiparameter gene prioritization were used to reveal candidate diagnostic biomarkers. Improved preprocessing and analysis were used to identify differentially expressed genes (DEGs), which led to 4651 DEGs enriched in metabolic pathways, immune response, and kidney development. Key transcription factors (TFs), including ZNF692, ZNF395, and ZNF582, were identified. Utilizing WGCNA, 21 hub genes were identified, and diagnostic potential was determined via ROC analysis. Seventeen of the genes with AUC > 0.7 were validated as diagnostic hub genes, including ALDH2, ACADM, KIF11, and PTPRC. Nine of these genes showed significant prognostic relevance. The current work identifies key biomarkers that can enhance ccRCC diagnosis and guide future therapy. - Source: PubMed
Publication date: 2026/02/02
Namdari HaidehRezaei FarhadKaramigolbaghi Maryam - Cervical cancer (CC) remains a significant global health burden despite advances in prevention and screening. Emerging evidence highlights the critical role of long non-coding RNAs (lncRNAs) and RNA modifications in tumorigenesis. Here, we identified LINC01094 as a highly expressed lncRNA in CC through TCGA analysis and clinical specimens. Functional studies, including CCK-8 method, flow cytometry, Transwell and Western blot assays, demonstrated that LINC01094 knockdown suppressed cell proliferation, migration, and epithelial-mesenchymal transition while promoting apoptosis in CC cells (Caski and SiHa). Mechanistically, NSUN2-mediated 5-methylcytosine methylation stabilized LINC01094, enhancing its expression in CC. Furthermore, LINC01094 facilitated ZNF582-dependent transcriptional activation of SIRT1, promoted the deacetylation and degradation of p53. Rescue experiments confirmed that ectopic expression of either LINC01094 or SIRT1 reversed the tumor-suppressive effects of NSUN2 or LINC01094 knockdown, respectively. Collectively, NSUN2-mediated stabilization of LINC01094 upregulated SIRT1 expression, thereby suppressing the p53 pathway and accelerating CC progression. These findings uncover a novel NSUN2/LINC01094/SIRT1 axis as an epigenetic-transcriptional driver of CC, offering potential therapeutic targets. - Source: PubMed
Publication date: 2026/02/03
Lu XiaYao LiliXu XuRexiti Mayinuer GuliHe XiaoliYang Yanyan